BC
MTNB icon

Boxer Capital’s Matinas BioPharma MTNB Stock Holding History

Boxer Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-229,573
Closed -$8.89M – 98
2021
Q2 		$8.89M Hold
229,573
– – 0.31% 68
2021
Q1 		$12.1M Hold
229,573
– – 0.41% 56
2020
Q4 		$15.6M Hold
229,573
– – 0.5% 49
2020
Q3 		$8.79M Hold
229,573
– – 0.3% 56
2020
Q2 		$8.87M Hold
229,573
– – 0.39% 49
2020
Q1 		$6.89M Buy
229,573
+25,807
+13% +$1.56M 0.47% 45
2019
Q4 		$23.1M Hold
203,766
– – 1.31% 21
2019
Q3 		$6.42M Hold
203,766
– – 0.47% 39
2019
Q2 		$8.73M Hold
203,766
– – 0.75% 25
2019
Q1 		$11.1M Buy
203,766
+90,909
+81% +$4.9M 1.28% 19
2018
Q4 		$3.36M Buy
+112,857
New +$4.43M 0.41% 22

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital's MTNB Position: Q3 2021 in Review

Boxer Capital sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 229,573 shares — an estimated $8.89M sold.

Boxer Capital first reported a position in MTNB in Q4 2018 and held it in 11 quarters. The position peaked at $23.1M in Q4 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

  • Boxer Capital reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
  • Boxer Capital sold 229,573 Matinas BioPharma shares in Q3 2021, an estimated $8.89M.
  • Boxer Capital first reported a position in Matinas BioPharma in Q4 2018 and held it in 11 quarters.
  • Boxer Capital's Matinas BioPharma position peaked at $23.1M in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.